Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 25Gastrointestinal 14Other hematologic neoplasm 13Head & Neck 5Thoracic 4Lymphoid 4Sarcoma 3Plasma cell 3Gynecologic 3Classical hematology 3Myeloid 2Other neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Multiple Myeloma 3073Neoplasms, Plasma Cell 614Lymphoma 455Lymphoma, Non-Hodgkin 428Recurrence 368Hodgkin Disease 366Leukemia, Lymphocytic, Chronic, B-Cell 362Precursor Cell Lymphoblastic Leukemia-Lymphoma 340Leukemia, Myeloid, Acute 322Leukemia 321Myelodysplastic Syndromes 287Lymphoma, Mantle-Cell 262Lymphoma, Large B-Cell, Diffuse 259Lymphoma, Follicular 254Lymphoma, B-Cell, Marginal Zone 231Burkitt Lymphoma 227Lymphoma, Large-Cell, Immunoblastic 203Myeloproliferative Disorders 197Neoplasms 181Immunoglobulin Light-chain Amyloidosis 181Hematologic Neoplasms 169Primary Myelofibrosis 167Leukemia, Myeloid, Chronic-Phase 165Leukemia, Myeloid, Accelerated Phase 154Lymphoma, T-Cell, Cutaneous 150Waldenstrom Macroglobulinemia 145Blast Crisis 143Leukemia, Myelomonocytic, Chronic 140Mycosis Fungoides 129Sezary Syndrome 128

Interventions

Thalidomide 1Dexamethasone 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Pathologic Complete Response × Plasma cell × Clear all
NCT01794572 2025-12-12

TOMMY

Institut Cancerologie de l'Ouest

Phase NA Terminated
13 enrolled 10 charts
Plasma cell

Pathologic Complete Response, Multiple Myeloma, Recurrence

NCT01134484 2012-07-20

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase 3 Unknown
480 enrolled
Plasma cell

Pathologic Complete Response, Multiple Myeloma

NCT00378222 2006-09-19

Autologous Transplantation for Multiple Myeloma

University of Bologna

Phase 3 Completed
324 enrolled
Plasma cell

Pathologic Complete Response, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡